Caris Life Sciences, Inc. (CAI) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Caris Life Sciences, Inc. (CAI) Healthcare & Pipeline Overview

Caris Life Sciences, Inc. leverages artificial intelligence and molecular profiling to personalize cancer treatment, offering tissue-based and blood-based solutions to biopharmaceutical customers. With a focus on data-driven insights and precision medicine, Caris operates in the competitive biotechnology sector, marked by innovation and regulatory scrutiny.

What Is the Investment Thesis for CAI?

The company's revenue growth is tied to the increasing adoption of personalized medicine and the demand for advanced diagnostic tools. With a market capitalization of $6.80B and a P/E ratio of 64.64, Caris operates with a profit margin of 3.7% and a gross margin of 53.1%. Key growth catalysts include expanding its pharma research and development services and further penetration into international markets. Potential risks include competition from established biotechnology firms and regulatory hurdles associated with diagnostic testing. The company's beta of 1.33 indicates higher volatility compared to the market.

Based on FMP financials and quantitative analysis

CAI Key Highlights

Market Cap of $6.80B reflects investor confidence in Caris's growth potential in the personalized medicine market.

• Gross Margin of 53.1% indicates strong pricing power and efficient cost management in its molecular profiling services.
• P/E Ratio of 64.64 suggests that investors have high expectations for future earnings growth.
• Profit Margin of 3.7% demonstrates the company's ability to convert revenue into profit, with room for improvement as the company scales.
• Beta of 1.33 indicates that the stock is more volatile than the market, which may attract risk-tolerant investors.

Who Are CAI's Competitors?

CAI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CAI's Key Strengths?

Proprietary AI-driven technology for molecular profiling.

• Comprehensive suite of tissue-based and blood-based solutions.
• Strong relationships with biopharmaceutical companies.
• Experienced leadership team.

What Are CAI's Weaknesses?

Relatively small profit margin compared to industry leaders.

• High P/E ratio indicates potential overvaluation.
• Dependence on regulatory approvals for diagnostic assays.
• Limited geographic presence compared to larger competitors.

What Could Drive CAI Stock Higher?

Expansion of international market presence in Europe and Asia (2027-2029).

• Development and commercialization of new diagnostic assays for specific cancer types.
• Strategic partnerships and acquisitions to expand capabilities and market reach.
• Integration of real-world data to enhance profiling services (2027).

What Are the Key Risks for CAI?

Rich valuation — a P/E of 64.64 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $14.6M recently.
• Increased competition from established biotechnology firms.
• Regulatory hurdles and changes in healthcare policies affecting diagnostic testing.
• Technological advancements by competitors rendering current technologies obsolete.
• Economic downturn affecting healthcare spending and demand for diagnostic services.

What Are the Growth Opportunities for CAI?

• Expansion of Pharma R&D Services: Caris has the opportunity to significantly grow its pharma research and development services. By leveraging its extensive molecular profiling data and AI capabilities, Caris can offer biopharmaceutical companies valuable insights for drug development and clinical trial design. The market for these services is estimated to reach $20 billion by 2030, presenting a substantial growth opportunity for Caris. Timeline: Ongoing.
• International Market Penetration: Caris can expand its molecular profiling services into international markets, particularly in Europe and Asia. These regions are experiencing increased demand for personalized medicine and advanced diagnostic tools. Establishing partnerships with local healthcare providers and research institutions will be crucial for successful market entry. The global market for molecular diagnostics is projected to reach $15 billion by 2028. Timeline: Upcoming: 2027-2029.
• Development of New Diagnostic Assays: Caris can invest in the development of new diagnostic assays that target specific cancer types or biomarkers. This will broaden its portfolio of molecular profiling services and attract a wider range of customers. The market for novel cancer diagnostics is expected to grow at a CAGR of 12% over the next five years. Timeline: Ongoing.
• Strategic Partnerships and Acquisitions: Caris can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. Collaborating with other companies in the biotechnology and healthcare sectors can provide access to new technologies, data, and distribution channels. Timeline: Ongoing.
• Integration of Real-World Data: Caris can integrate real-world data (RWD) from electronic health records and other sources to enhance its molecular profiling services. RWD can provide valuable insights into patient outcomes and treatment effectiveness, further improving the accuracy and utility of Caris's diagnostic tools. The market for RWD in healthcare is projected to reach $10 billion by 2027. Timeline: Upcoming: 2027.

What Are CAI's Competitive Advantages?

• Proprietary AI-driven molecular profiling technology.
• Extensive database of molecular information.
• Strong relationships with biopharmaceutical companies.
• Comprehensive suite of molecular profiling services.

What Does CAI Do?

Founded in 2008 and headquartered in Irving, Texas, Caris Life Sciences, Inc. is an artificial intelligence TechBio company focused on transforming healthcare through molecular information and machine learning algorithms. The company's core business revolves around providing molecular profiling services, both in the United States and internationally. Caris's portfolio includes MI Profile, a tissue-based molecular profiling solution, and Caris Assure, a blood-based molecular profiling solution, both designed to inform cancer treatment decisions. These services enable oncologists to gain deeper insights into the unique molecular characteristics of a patient's cancer, facilitating more personalized and effective treatment strategies. Beyond its direct patient care applications, Caris also offers pharma research and development services. These services encompass laboratory delivery, strategic data analysis, and research support, catering to the needs of biopharmaceutical companies seeking to develop new cancer therapies. By integrating advanced molecular profiling with sophisticated AI, Caris aims to accelerate the development and commercialization of innovative cancer treatments, positioning itself at the forefront of precision medicine.

What Products and Services Does CAI Offer?

• Provides tissue-based molecular profiling solutions (MI Profile).
• Offers blood-based molecular profiling solutions (Caris Assure).
• Develops and commercializes solutions using molecular information.
• Utilizes machine learning algorithms to transform healthcare.
• Offers laboratory delivery services to biopharmaceutical customers.
• Provides strategic data and research services.

How Does CAI Make Money?

• Generates revenue through molecular profiling services for cancer treatment.
• Offers pharma research and development services to biopharmaceutical companies.
• Leverages AI and machine learning to enhance diagnostic accuracy and treatment personalization.

What Industry Does CAI Operate In?

Caris Life Sciences operates within the rapidly evolving biotechnology industry, characterized by advancements in genomics, proteomics, and artificial intelligence. The market for molecular profiling is expanding as personalized medicine gains traction, driven by the need for more targeted and effective cancer treatments. Caris competes with companies like Moderna, Inc. (MRNA) and Jazz Pharmaceuticals plc (JAZZ), each with its own focus and strengths. The industry is subject to stringent regulatory oversight and requires substantial investment in research and development. Caris's AI-driven approach differentiates it from traditional diagnostic companies, positioning it to capitalize on the growing demand for data-driven insights in healthcare.

Who Are CAI's Key Customers?

• Oncologists and other healthcare providers.
• Biopharmaceutical companies.
• Research institutions.

Caris Life Sciences, Inc. (CAI) Valuation Context

Valued at $6.80B, CAI is classified as a mid-cap stock. Analyst price targets span from $21.00 to $33.00, with a consensus of $26.00. At the current price of $24.04, that implies approximately 8% upside potential. Relative to its peer group, CAI's quantitative score of 82/100 is above the peer average of 57/100.

CAI Revenue & Earnings Trend

In Jun 2026, CAI generated $263.7M in top-line revenue, marking a sequential increase of 22.0%. The company recorded a net loss of $637K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, CAI averaged $0.09 in diluted EPS.

Company Profile

Caris Life Sciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Irving, US. The company is led by CEO David Dean Halbert. CAI has traded publicly since 2025.

Return on equity for Caris Life Sciences, Inc. stands at 6.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.9%, showing how much profit it generates from its asset base. CAI trades at a trailing price-to-earnings ratio of 64.64, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 2.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.05 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.7%, the inverse of the P/E and a quick read on earnings relative to price.

Caris Life Sciences, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.55 places it in the safe zone, indicating low near-term bankruptcy risk.

Caris Life Sciences, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 387.7% above estimates on average.

Wall Street analysts project Caris Life Sciences, Inc. revenue of about $1.03B for fiscal 2026, with EPS near $0.12. The estimate reflects 10 contributing analysts.

Over the past six months, Caris Life Sciences, Inc. insiders filed 24 SEC Form 4 transactions — 10 sales and 14 purchases. On net that is roughly 474K shares disposed (about $14.6M), a signal worth weighing alongside the fundamentals.

CAI Financials

CAI Latest News

CAI Analyst Consensus

CAI MoonshotScore

Caris Life Sciences, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources